Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.2552W HIGH $13.50
Volume
1.86 K
Value Traded
1.40 M
Short % Float
8.32%
-4.9%Week
+4.3%1 Month
-38.12%3 Month
-36.5%6 Month
-96.64%5 Year
-96.54%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
49.77 M
EPS (TTM)
-2.78
P/E Ratio
-
Ent. Value
58.35 M
Total Shares
12.99 M
Float Shares
11.01 M
Insiders
22.56%
Institutions
22.64%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CLNN Catalyst Timeline
Dated clinical, regulatory and corporate events for Clene Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Clene Inc.
398Total events
10Upcoming
86Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Pricing of $4 million registered direct offering of 1,219,513 shares at $3.28 per share
●NDA SubmissionCNMAu8FiledRegulatory Filing
NDA submission for CNM-Au8 under accelerated approval pathway
ALSsource ↗
◆Timing GuidanceCNMAu8FiledPresentation
Plan to file NDA for CNM-Au8 in ALS under accelerated approval pathway
ALSsource ↗
▲FDA Feedback ReceivedCNMAu8FiledFDA Meeting
FDA Type C meeting minutes confirm NfL data may support accelerated approval NDA
ALSsource ↗
▼Equity OfferingCorporate
Closed underwritten registered direct common stock offering for $7.0 million
●Debt Royalty FinancingCorporate
Amended senior secured convertible debt facilities to extend maturity to August 2027
▲FDA Feedback ReceivedCNMAu8FiledFDA Meeting
FDA meeting minutes confirm ability to file NDA under accelerated approval
ALSsource ↗
◆FDA Feedback ReceivedCNMAu8FiledFDA Meeting
Formal written meeting minutes from Type C FDA meeting expected
ALSsource ↗
●NDA SubmissionCNMAu8FiledRegulatory Filing
NDA submission to FDA for CNM-Au8 via accelerated approval pathway
ALSsource ↗
◆Runway Guidance UpdateCorporate
Cash runway guidance: initial tranche provides runway to end of Q3 2026; potential additional tranches extend into 2027
◆Type C MeetingCNMAu8FiledFDA Meeting
In-person Type C FDA meeting to discuss CNM-Au8 biomarker and survival data
ALSsource ↗
▲Biomarker DataCNMAu8FiledClinical Data
New exploratory biomarker findings: IGFBP7 decline associated with improved survival
amyotrophic lateral sclerosis (ALS)source ↗
◆Timing GuidanceCNMAu8FiledPresentation
Planned NDA submission under accelerated approval pathway
ALSsource ↗
◆Type C MeetingCNMAu8FiledFDA Meeting
FDA Type C Meeting to discuss biomarker data and potential accelerated approval pathway
amyotrophic lateral sclerosis (ALS)source ↗
▲Equity OfferingCorporate
Oversubscribed registered direct offering of over $28 million completed in January 2026
▲Trial InitiationCNMAu8FiledTrial
First patient dosed in confirmatory Phase 3 RESTORE-ALS trial
ALSsource ↗
◆R&D DayPresentation
Clene management to host 1x1 investor meetings at Benchmark 14th Annual Discovery One-on-One Investor Conference
▲Full ResultsCNMAu8FiledClinical Data
Statistically significant reductions in NfL and GFAP in CNM-Au8 treated ALS patients
ALSsource ↗
▲Topline ReadoutCNMAu8FiledClinical Data
Statistically significant NfL and GFAP reductions and survival improvement from HEALEY ALS Platform Trial and EAP
amyotrophic lateral sclerosis (ALS)source ↗
▲Biomarker DataCNMAu8FiledClinical Data
Completion of FDA-recommended biomarker analyses showing statistically significant reductions in NfL and GFAP
ALSsource ↗
◆Oral PresentationPresentation
Clene management to participate in panel discussion at Maxim Growth Summit
◆Timing GuidanceCNMAu8FiledPresentation
NDA submission for potential Accelerated Approval of CNM-Au8 in ALS
ALSsource ↗
◆Topline ReadoutCNMAu8FiledClinical Data
Analysis of NfL biomarker data from NIH-sponsored EAP
ALSsource ↗
◆Oral PresentationCNMAu8FiledPresentation
Presentation of combined REPAIR-MS results at ECTRIMS 2025
multiple sclerosissource ↗
▲Full ResultsCNMAu8FiledClinical Data
Combined REPAIR-MS results showing improvement in brain NAD+/NADH ratio
multiple sclerosissource ↗
◆Oral PresentationPresentation
Clene management presentation at H.C. Wainwright 27th Annual Global Investment Conference
◆Poster PresentationCNMAu8FiledPresentation
Preclinical data presented at Michael J. Fox Foundation H2 Therapeutics Stewardship Meeting
Parkinson's diseasesource ↗
▲Preclinical PoCCNMAu8FiledPreclinical
Preclinical proof-of-concept in dopaminergic neuron model of PD
Parkinson's diseasesource ↗
●End Of Phase 2 MeetingCNMAu8FiledFDA Meeting
Type B end-of-Phase 2 meeting with FDA for MS program
MSsource ↗
●Oral PresentationCNMAu8FiledPresentation
Presented combined Phase 2 REPAIR-MS results at ECTRIMS 2025
MSsource ↗
▲Preclinical PoCCNMAu8FiledPreclinical
New preclinical data in Parkinson's disease model announced
PDsource ↗
Past FDA Catalysts and PDUFA Decisions
How CLNN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-06-30 | CNM-Au8 | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C48 / 100
Pipeline Score
$75M
Pipeline Value
Fair Value
Valuation Signal
3
Drugs Scored
1.5x
rNPV / MCap
Top 21%
Micro Cap(rank 139 of 658)
Percentile Rank
Clene Inc. carries a moderate pipeline score (48/100), with $2.7B risk-adjusted pipeline value, led by CNMAu8 in Relapsing Multiple Sclerosis (Phase 2), across $81B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CNMAu8 Small moleculeNCT05299658 | Amyotrophic Lateral Sclerosis | Phase 2 | ACTIVE NOT_RECRUITING | 246 | Aug 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every CLNN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CNM-Au8 Accelerated | Multiple Sclerosis | Phase 2 | 2025-09-25 | n: 39; cohort 1 n: 11; cohort 2 n: 15; cohort pd n: 13Read More | Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis PatientsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| McLaughlin VallerieDirector | Grant/Award | 1,500 1,500 held | $0.00 | 05/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CLNN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Boxer Capital Management, LLC | 0.2 % (-33.3 %) | 2.94 M | 477.51 K |
CLNN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CLNN ranks across every disease it competes in
Competitive Position is a premium feature
See how CLNN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCLNN News
CLNNClene to Present at Upcoming Investor Conferences
Clene Inc. (Nasdaq: CLNN) has announced its participation in two upcoming investor conferences, the 5th Annual ROTH Healthcare Opportunities Conference and the Lytham Partners Investor Conference Fall Event. Both events will feature 1x1 meetings with investors, and Clene will present its investigational therapy, CNM-Au8, which targets mitochondrial health to treat neurodegenerative diseases. The presentations will be accessible via webcast.
Read more →CLNNClene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
Clene Inc. has successfully closed a $4 million registered direct offering, primarily led by its Chairman and existing shareholders. This funding is expected to sustain the company through mid-first quarter 2027, beyond the anticipated FDA decision regarding the CNM-Au8 NDA for ALS treatment. The offering was executed without intermediaries, reflecting a direct approach to capital raising.
Read more →CLNN▲ +22.6%on this news· ran to +33% by day 3
Clene Announces $4 Million Registered Direct Offering
Clene Inc. has announced a registered direct offering of 1,219,513 shares at $3.28 each, raising $4 million. The offering, led by the company's Chairman and other insiders, is set to close on September 17, 2026. Proceeds will fund operations through mid-first quarter 2027, supporting regulatory efforts for its investigational therapy, CNM-Au8.
Read more →CLNNClene to Present at Upcoming September Investor Conferences
Clene Inc. announced its participation in two upcoming investor conferences in September 2026. The company will present at the Cantor Global Healthcare Conference on September 9 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15. Both events will include 1x1 investor meetings, providing opportunities for direct engagement with management.
Read more →CLNNClene to Present at the Emerging Growth Conference
Clene Inc. (Nasdaq: CLNN) will present at the Emerging Growth Conference on August 19, 2026, at 3:10 p.m. ET. The presentation will be available via webcast, allowing investors to access updates on the company's developments. Clene focuses on treating neurodegenerative diseases with its investigational therapy, CNM-Au8.
Read more →CLNNClene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
Clene Inc. reported its second quarter 2026 financial results, highlighting plans to submit a New Drug Application for CNM-Au8 for ALS under the accelerated approval pathway. The company presented new data indicating survival benefits for patients treated with CNM-Au8, which may support their NDA submission. However, Clene also reported a significant net loss during the quarter.
Read more →CLNNClene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval
Clene Inc. announced promising results from biomarker analyses of its ALS treatment, CNM-Au8, indicating that patients with a decline or stabilization in neurofilament light chain (NfL) levels experienced significant survival and functional benefits. These findings will support Clene's New Drug Application (NDA) for accelerated approval from the FDA, which recognizes NfL as a potential surrogate endpoint. The analyses derived from two Phase 2 trials suggest a strong correlation between NfL response and improved clinical outcomes.
Read more →CLNN▼ -5.4%on this news
Clene to Present at The Canaccord 46th Annual Growth Conference
Clene Inc. will present at the Canaccord 46th Annual Growth Conference on August 11, 2026, at 10:30 am ET in Boston, MA. The presentation will focus on their innovative therapies for neurodegenerative diseases such as ALS and MS. Clene aims to improve mitochondrial health and neuronal function through its investigational therapy, CNM-Au8.
Read more →CLNN▲ +8.5%on this news
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
Clene Inc. reported its first quarter financial results for 2026, highlighting a successful FDA Type C meeting that indicated the potential for accelerated approval of CNM-Au8 for ALS. The company plans to submit a New Drug Application in Q3 of 2026 and initiate a Phase 3 trial in early 2027. Financially, Clene has raised over $28 million through a registered direct offering and amended its debt facility to enhance liquidity. Despite a reported net loss of $8.1 million, the company remains optimistic about its progress in developing treatments for neurodegenerative diseases.
Read more →CLNN▼ -18.7%on this news
Clene Announces $7 Million Underwritten Offering of Common Stock
Clene Inc. has announced a $7 million underwritten offering of common stock at $7.00 per share. The funds will primarily be used for general corporate purposes, including the preparation of a New Drug Application for its lead drug candidate, CNM-Au8. The offering is set to close on or about May 6, 2026, pending customary conditions.
Read more →CLNN▼ -18.7%on this news
Clene to Present at Upcoming May Conferences
Clene Inc. will participate in two investor conferences in May 2026, focusing on its innovative therapies for neurodegenerative diseases. The Emerging Growth Conference will feature a virtual presentation on May 6, while the D. Boral Capital Global Conference will include one-on-one meetings on May 7. Clene aims to highlight its late-stage clinical developments and commitment to improving mitochondrial health.
Read more →CLNN▲ +31.8%on this newsshared move
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
Clene Inc. has received encouraging feedback from the FDA regarding its investigational drug CNM-Au8 for ALS. The FDA indicated that the data provided may support an NDA submission under the accelerated approval pathway, with NfL biomarker data potentially serving as a surrogate endpoint. Clene plans to submit the NDA in Q3 2026, marking a significant milestone for the company and the ALS community.
Read more →CLNN▲ +6.1%on this news
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
Clene Inc. reported its full year 2025 financial results, highlighting an upcoming Type C meeting with the FDA regarding its CNM-Au8 program for ALS. The company anticipates filing a new drug application (NDA) under an accelerated approval pathway by mid-2026, supported by positive biomarker data. Clene's recent financing efforts aim to extend its operational runway into 2027, despite reporting a significant net loss for the year.
Read more →CLNN▲ +9.8%on this news
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts
Clene Inc. has issued a letter to stockholders detailing key regulatory and clinical milestones for its drug CNM-Au8 in 2026. The company plans to submit a New Drug Application (NDA) to the FDA, aiming for accelerated approval based on promising clinical data. Clene has also secured funding to support its operations and plans to initiate a Phase 3 trial later this year.
Read more →CLNN▼ -6.3%on this news
Clene to Present at the Emerging Growth Conference - January 16, 2026
Clene Inc. will present at the Emerging Growth Conference on January 21, 2026, focusing on their advancements in treating neurodegenerative diseases. The presentation will be available via webcast, allowing broad access for investors. Clene's innovative approach targets mitochondrial health to improve neuronal function.
Read more →CLNNClene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
Clene Inc. announced that the FDA has scheduled an in-person Type C Meeting to discuss its biomarker data supporting the potential NDA filing for CNM-Au8. The company presented significant reductions in neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) linked to survival outcomes in ALS patients. New analyses also identified IGFBP7 as a promising biomarker associated with improved survival, although these findings are exploratory and need further validation.
Read more →CLNN▲ +7.1%on this newsshared move
Clene Announces Registered Direct Offering of Over $28 Million
Clene Inc. announced a registered direct offering of over $28 million, aimed at supporting its ongoing efforts in treating neurodegenerative diseases, particularly ALS. The offering attracted notable investors, including Boxer Capital and Vivo Capital. The proceeds will help fund Clene's planned New Drug Application for its investigational therapy, CNM-Au8, expected in 2026.
Read more →About Clene Inc.
Headquarters6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT, 84121
BIOPHARMAWATCH ELITE PLUS
Trade the next CLNN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime